Dr. Baddley has served as a consultant on the Merck Advisory Board and received a fee (less than $10,000).
Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases
Version of Record online: 27 MAR 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 4, pages 612–615, April 2012
How to Cite
Bharat, A., Xie, F., Baddley, J. W., Beukelman, T., Chen, L., Calabrese, L., Delzell, E., Grijalva, C. G., Patkar, N. M., Saag, K., Winthrop, K. L. and Curtis, J. R. (2012), Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res, 64: 612–615. doi: 10.1002/acr.21564
- Issue online: 27 MAR 2012
- Version of Record online: 27 MAR 2012
- Accepted manuscript online: 12 DEC 2011 01:10PM EST
- Manuscript Accepted: 5 DEC 2011
- Manuscript Received: 6 JUN 2011
- Agency for Healthcare Research and Quality. Grant Numbers: U18-HS17919, R01-HS018517, 1K08HS017551-01, R01HS018517
- NIHvia the University of Alabama at Birmingham Center for Clinical and Translational Science. Grant Number: 5KL2-RR025776-03
- NIH. Grant Numbers: 5P60AR56116, AR053351
- 11Progressive multifocal leukoencephalopathy after rituximab therapy in a patient with mantle cell lymphoma. Rinsho Ketsueki 2010; 51: 1786–8. In Japanese., , , , , , et al.
- 19Progressive multifocal leukoencephalopathy associated with biologic and synthetic DMARD therapy in rheumatic diseases: an analysis of the FDA Adverse Event Reporting System database [abstract]. Arthritis Rheum 2010; 62 Suppl: S292., .